Rockwell Medical (NASDAQ:RMTI) Raised to Hold at Wall Street Zen

Rockwell Medical (NASDAQ:RMTI) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

A number of other equities research analysts have also issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rockwell Medical in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $2.50 target price on shares of Rockwell Medical in a report on Monday, January 26th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $2.50.

Rockwell Medical Price Performance

NASDAQ:RMTI opened at $0.87 on Friday. Rockwell Medical has a one year low of $0.78 and a one year high of $2.10. The stock has a market cap of $34.29 million, a PE ratio of -5.80 and a beta of 1.71. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.63 and a current ratio of 3.98. The stock has a 50 day moving average price of $1.01 and a 200 day moving average price of $1.04.

Rockwell Medical (NASDAQ:RMTI) last issued its earnings results on Thursday, March 26th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). The firm had revenue of $18.35 million for the quarter, compared to analysts’ expectations of $18.58 million. Rockwell Medical had a negative return on equity of 15.64% and a negative net margin of 7.67%. Equities research analysts expect that Rockwell Medical will post 0.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Rockwell Medical

Several hedge funds have recently made changes to their positions in RMTI. Panagora Asset Management Inc. purchased a new position in Rockwell Medical in the 2nd quarter valued at $41,000. XTX Topco Ltd boosted its holdings in shares of Rockwell Medical by 286.5% in the fourth quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after acquiring an additional 46,029 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Rockwell Medical during the fourth quarter worth about $84,000. GSA Capital Partners LLP raised its holdings in Rockwell Medical by 635.1% during the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock worth $197,000 after purchasing an additional 141,672 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Rockwell Medical by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after purchasing an additional 41,668 shares during the period. Hedge funds and other institutional investors own 23.31% of the company’s stock.

Rockwell Medical News Summary

Here are the key news stories impacting Rockwell Medical this week:

• Positive Sentiment: Achieved adjusted EBITDA profitability for the second straight year, showing improved operating leverage that can support the path to sustainable profitability. Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results
• Positive Sentiment: Featured in Zacks screens as a value/momentum candidate — this can attract bargain hunters and momentum traders looking for turnaround stories. Should Value Investors Buy Rockwell Medical (RMTI) Stock?
• Neutral Sentiment: Full Q4 earnings call/transcript provides management commentary and color on drivers of the quarter and the FY26 outlook — useful for investors who want to hear management’s execution plan and assumptions. Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Q4 results missed revenue estimates and reported EPS came in below some consensus figures, signaling slower top‑line momentum; several outlets flagged the revenue decline as the main driver of investor concern. Rockwell Medical (RMTI) Reports Q4 Loss, Misses Revenue Estimates
• Negative Sentiment: Management’s cost‑cutting/right‑sizing plan has raised execution risk and could pressure future growth if not managed carefully — analysts flagged this as a demand/execution risk that may weigh on investor confidence. Rockwell Medical’s Cost Cuts Raise Execution Risk and Threaten Future Growth Prospects
• Negative Sentiment: Company issued a FY26 outlook that some market coverage characterized as cautious after the quarter; investors typically punish missed top‑line results and uncertain guidance more than one‑time positives. Rockwell Medical misses top-line estimates; gives FY26 outlook

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.